CBT
ALXN

Central Bank & Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Central Bank & Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-43
Closed -$8K – 380
2015
Q4 		$8K Buy
+43
New +$7.51K ﹤0.01% 299
2015
Q3 		– Sell
-12
Closed -$2K – 413
2015
Q2 		$2K Buy
+12
New +$2.07K ﹤0.01% 369

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Central Bank & Trust's ALXN Position: Q1 2016 in Review

Central Bank & Trust sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 43 shares — an estimated $8K sold.

Central Bank & Trust first reported a position in ALXN in Q2 2015 and held it in 2 quarters. The position peaked at $8K in Q4 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Central Bank & Trust reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Central Bank & Trust sold 43 Alexion Pharmaceuticals shares in Q1 2016, an estimated $8K.
  • Central Bank & Trust first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Central Bank & Trust's Alexion Pharmaceuticals position peaked at $8K in Q4 2015.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Central Bank & Trust's 13F filing for Q1 2016, filed 11 Apr 2016.